Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Poll|Articles|March 6, 2025
Poll: Pressing Ethical Issues
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- Ethical issues in psychiatry include balancing patient autonomy with necessary interventions and confidentiality with the duty to warn.
- Emerging technologies in psychiatric treatment present new ethical challenges that require careful consideration and dialogue.
We want to hear from you: what ethical issues in psychiatry are you most worried about?
Advertisement
March is Ethics Awareness Month. To honor the occasion, we want to hear from you about the most pressing ethical issues in psychiatry. Take the poll here:
Which of the following are you most concerned about?
Which of the following are you most concerned about?
How frequently would you say you encounter an ethical quandary in your practice?
Have you read any articles on ethics-related topics in Psychiatric Times?
Would you like to see more on ethics in Psychiatric Times?
If you are interested in writing on ethics or suggesting a topic, please email us at PTEditor@mmhgroup.com!
Advertisement
Related to this article
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
5